|
1
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oakman C, Santarpia L and Di Leo A: Breast
cancer assessment tools and optimizing adjuvant therapy. Nat Rev
Clin Oncol. 7:723–732. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wirapati P, Sotiriou C, Kunkel S, Farmer
P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag
T, Schütz F, et al: Meta-analysis of gene expression profiles in
breast cancer: toward a unified understanding of breast cancer
subtyping and prognosis signatures. Breast Cancer Res. 10:R652008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigelt B, Hu Z, He X, Livasy C, Carey LA,
Ewend MG, Glas AM, Perou CM and Van’t Veer LJ: Molecular portraits
and 70-gene prognosis signature are preserved throughout the
metastatic process of breast cancer. Cancer Res. 65:9155–9158.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parker JS, Mullins M, Cheang MC, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Correa Geyer F and Reis-Filho JS:
Microarray-based gene expression profiling as a clinical tool for
breast cancer management: are we there yet? Int J Surg Pathol.
17:285–302. 2009.PubMed/NCBI
|
|
7
|
Cosler LE and Lyman GH: Economic analysis
of gene expression profile data to guide adjuvant treatment in
women with early-stage breast cancer. Cancer Invest. 27:953–959.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perou CM, Sorlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng Y, Li X, Sun B, Wang Y, Zhang L, Pan
X, Chen X, Wang X, Wang J and Hao X: Evidence for a transcriptional
signature of breast cancer. Breast Cancer Res Treat. 122:65–75.
2009. View Article : Google Scholar
|
|
10
|
Creighton CJ, Fu X, Hennessy BT, Casa AJ,
Zhang Y, Gonzalez- Angulo AM, Lluch A, Gray JW, Brown PH and
Hilsenbeck S: Proteomic and transcriptomic profiling reveals a link
between the PI3K pathway and lower estrogen-receptor (ER) levels
and activity in ER+ breast cancer. Breast Cancer Res.
12:R402010. View
Article : Google Scholar
|
|
11
|
Chernov AV, Baranovskaya S, Golubkov VS,
Wakeman DR, Snyder EY, Williams R and Strongin AY: Microarray-based
transcriptional and epigenetic profiling of matrix
metalloproteinases, collagens, and related genes in cancer. J Biol
Chem. 285:19647–19659. 2010. View Article : Google Scholar
|
|
12
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miecznikowski JC, Wang D, Liu S, Sucheston
L and Gold D: Comparative survival analysis of breast cancer
microarray studies identifies important prognostic genetic
pathways. BMC Cancer. 10:5732010. View Article : Google Scholar
|
|
14
|
Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim
MS, Chaerkady R, Gucek M, Cole RN, Sukumar S and Pandey A:
Proteomic characterization of Her2/neu-overexpressing breast cancer
cells. Proteomics. 16:3600–3610. 2010.
|
|
15
|
Tebbit CL, Zhai J, Untch BR, Ellis MJ,
Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR
and Olson JA Jr: Novel tumor sampling strategies to enable
microarray gene expression signatures in breast cancer: a study to
determine feasibility and reproducibility in the context of
clinical care. Breast Cancer Res Treat. 118:635–643. 2009.
View Article : Google Scholar
|
|
16
|
Centeno BA, Enkemann SA, Coppola D,
Huntsman S, Bloom G and Yeatman TJ: Classification of human tumors
using gene expression profiles obtained after microarray analysis
of fine-needle aspiration biopsy samples. Cancer. 105:101–109.
2005. View Article : Google Scholar
|
|
17
|
Stathopoulos GP and Armakolas A:
Differences in gene expression between individuals with multiple
primary and single primary malignancies. Int J Mol Med. 24:613–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sørlie T: Molecular classification of
breast tumors: toward improved diagnostics and treatments. Methods
Mol Biol. 360:91–114. 2007.PubMed/NCBI
|
|
19
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: hnRNP C is required for postimplantation mouse
development but Is dispensable for cell viability. Mol Cell Biol.
20:4094–4105. 2000.PubMed/NCBI
|
|
20
|
Adachi Y, Pavlakis GN and Copeland TD:
Identification and characterization of SET, a nuclear
phosphoprotein encoded by the translocation break point in acute
undifferentiated leukemia. J Biol Chem. 269:2258–2262. 1994.
|
|
21
|
Canela N, Rodriguez-Vilarrupla A, Estanyol
JM, Diaz C, Pujol MJ, Agell N and Bachs O: The SET protein
regulates G2/M transition by modulating cyclin B-cyclin-dependent
kinase 1 activity. J Biol Chem. 278:1158–1164. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ozbek U, Kandilci A, van Baal S, et al:
SET-CAN the product of t(9;9) in acute undifferentiated leukaemia,
causes expansion of early haematopoietic progenitors and
hyperproliferation of stomach mucosa in transgenic mice. Am J
Pathol. 171:654–666. 2007. View Article : Google Scholar
|
|
23
|
Ralph S, Brenchley PE, Summers A, Rosa DD,
Swindell R and Jayson GC: Heparanase gene haplotype (CGC) is
associated with stage of disease in patients with ovarian
carcinoma. Cancer Sci. 98:844–849. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
|
|
25
|
Lutz M, Wempe F, Bahr I, Zopf D and von
Melchner H: Proteasomal degradation of the multifunctional
regulator YB-1 is mediated by an F-Box protein induced during
programmed cell death. FEBS Lett. 580:3921–3930. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Antonicka H, Ostergaard E, Sasarman F,
Weraarpachai W, Wibrand F, Pedersen AM, Rodenburg RJ, van der Knaap
MS, Smeitink JA, Chrzanowska-Lightowlers ZM and Shoubridge EA:
Mutations in C12orf65 in patients with encephalomyopathy and a
mitochondrial translation defect. Am J Hum Genet. 87:115–122. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sowa ME, Bennett EJ, Gygi SP and Harper
JW: Defining the human deubiquitinating enzyme interaction
landscape. Cell. 138:389–403. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torrini M, Marchese C, Vanzetti M, Marini
V, Origone P, Garré C and Mareni C: Mutation analysis of
oxisterol-binding-protein gene in patients with age-related macular
degeneration. Genet Test. 11:421–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen D, Zhang Z, Li M, Wang W, Li Y,
Rayburn ER, Hill DL, Wang H and Zhang R: Ribosomal protein S7 as a
novel modulator of p53-MDM2 interaction: binding to MDM2,
stabilization of p53 protein, and activation of p53 function.
Oncogene. 26:5029–5037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Costanzo M, Baryshnikova A, Bellay J, Kim
Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et
al: The genetic landscape of a cell. Science. 22: 327:425–431.
2010.
|
|
31
|
Doong H, Rizzo K, Fang S, Kulpa V,
Weissman AM and Kohn EC: CAIR-1/BAG-3 abrogates heat shock
protein-70 chaperone complex-mediated protein degradation:
accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol
Chem. 278:28490–28500. 2003. View Article : Google Scholar
|
|
32
|
Du X, Nagata S, Ise T, Stetler-Stevenson M
and Pastan I: FCRL1 on chronic lymphocytic leukemia, hairy cell
leukemia, and B-cell non-Hodgkin lymphoma as a target of
immunotoxins. Blood. 111:338–343. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Malek SN, Dordai DI, Reim J, et al:
Malignant transformation of early lymphoid progenitors in mice
expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci
USA. 95:7351–7356. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tschumper RC, Geyer SM, Campbell ME, et
al: Immunoglobulin diversity gene usage predicts unfavorable
outcome in a subset of chronic lymphocytic leukemia patients. J
Clinc Invest. 118:306–315. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vitek L and Schwertner HA: The heme
catabolic pathway and its protective effects on oxidative
stress-mediated diseases. Adv Clin Chem. 43:1–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mani A and Gelmann EP: The
ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol.
23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yanagisawa M, Huveldt D, Kreinest P, et
al: p120 catenin isoform switch affects Rho activity, induces tumor
cell invasion and predicts metastatic disease. J Biol Chem.
283:18344–18354. 2008. View Article : Google Scholar
|
